Bhuvana Veeraragavan
Senior Partner
BangalorePractice Area
Sectors
I would like to be the bridge between investors and founders to translate legal speak to business speak and getting the deal done. I believe in building partnerships and understanding business needs to ensure that it is a 'win-win' for all.
As a seasoned professional with 16 years of experience, Bhuvana has worked across sectors, establishing herself as a go-to lawyer in the PE/ VC, M&A and general corporate space. Bhuvana’s work experience includes prominent industry leaders such as TPG, Warburg Pincus, WestBridge Capital, Tiger Global, Valar Ventures, and Wipro Limited. Known for her solution-oriented approach, Bhuvana focuses on providing innovative legal strategies and practical solutions. Bhuvana’s track record includes working on marquee deals that have garnered significant attention and recognition within the industry. Her attention to detail, strong negotiation skills, and deep knowledge of Indian corporate law have consistently contributed to securing favorable outcomes for her clients.
WORK HIGHLIGHTS
-
On its USD 350 million fund raise from Prosus Ventures, TPG and existing investors (Pharmeasy became the first unicorn in the Indian e-pharmacy segment)
-
On the USD 120 million sale of its biopharma division to Recipharm
-
On the promoters’ divestment, involving a USD 1 billion transaction
-
On its investment in Hella.Infra Market, Groww Inc, Moglix, Spinny and Progcap
-
On its investments into Quikr Mauritius Holding Private Limited, and into Capillary Technologies International Pte. Ltd.
-
On (i) The Indian aspects of its USD 1.45 billion acquisition of Capco (ii) Its USD 80 million acquisition of Eximius Design (iii) Its USD 13 million acquisition of Encore Theme Technologies (iv) Its USD 117 million acquisition of Alight HR Services India Private Limited backed by a USD 1.6 billion, 10-year outsourcing contract
-
On its USD 350 million fund raise from Prosus Ventures, TPG and existing investors (Pharmeasy became the first unicorn in the Indian e-pharmacy segment)
-
On the USD 120 million sale of its biopharma division to Recipharm
-
On the promoters’ divestment, involving a USD 1 billion transaction
-
On its investment in Hella.Infra Market, Groww Inc, Moglix, Spinny and Progcap
-
On its investments into Quikr Mauritius Holding Private Limited, and into Capillary Technologies International Pte. Ltd.
-
On (i) The Indian aspects of its USD 1.45 billion acquisition of Capco (ii) Its USD 80 million acquisition of Eximius Design (iii) Its USD 13 million acquisition of Encore Theme Technologies (iv) Its USD 117 million acquisition of Alight HR Services India Private Limited backed by a USD 1.6 billion, 10-year outsourcing contract
-
On its USD 350 million fund raise from Prosus Ventures, TPG and existing investors (Pharmeasy became the first unicorn in the Indian e-pharmacy segment)
-
On the USD 120 million sale of its biopharma division to Recipharm
-
On the promoters’ divestment, involving a USD 1 billion transaction
-
On its investment in Hella.Infra Market, Groww Inc, Moglix, Spinny and Progcap
-
On its investments into Quikr Mauritius Holding Private Limited, and into Capillary Technologies International Pte. Ltd.
-
On (i) The Indian aspects of its USD 1.45 billion acquisition of Capco (ii) Its USD 80 million acquisition of Eximius Design (iii) Its USD 13 million acquisition of Encore Theme Technologies (iv) Its USD 117 million acquisition of Alight HR Services India Private Limited backed by a USD 1.6 billion, 10-year outsourcing contract
-
On its USD 350 million fund raise from Prosus Ventures, TPG and existing investors (Pharmeasy became the first unicorn in the Indian e-pharmacy segment)
-
On the USD 120 million sale of its biopharma division to Recipharm
-
On the promoters’ divestment, involving a USD 1 billion transaction
-
On its investment in Hella.Infra Market, Groww Inc, Moglix, Spinny and Progcap
-
On its investments into Quikr Mauritius Holding Private Limited, and into Capillary Technologies International Pte. Ltd.
-
On (i) The Indian aspects of its USD 1.45 billion acquisition of Capco (ii) Its USD 80 million acquisition of Eximius Design (iii) Its USD 13 million acquisition of Encore Theme Technologies (iv) Its USD 117 million acquisition of Alight HR Services India Private Limited backed by a USD 1.6 billion, 10-year outsourcing contract
-
On its USD 350 million fund raise from Prosus Ventures, TPG and existing investors (Pharmeasy became the first unicorn in the Indian e-pharmacy segment)
-
On the USD 120 million sale of its biopharma division to Recipharm
-
On the promoters’ divestment, involving a USD 1 billion transaction
-
On its investment in Hella.Infra Market, Groww Inc, Moglix, Spinny and Progcap
-
On its investments into Quikr Mauritius Holding Private Limited, and into Capillary Technologies International Pte. Ltd.
-
On (i) The Indian aspects of its USD 1.45 billion acquisition of Capco (ii) Its USD 80 million acquisition of Eximius Design (iii) Its USD 13 million acquisition of Encore Theme Technologies (iv) Its USD 117 million acquisition of Alight HR Services India Private Limited backed by a USD 1.6 billion, 10-year outsourcing contract
-
On its USD 350 million fund raise from Prosus Ventures, TPG and existing investors (Pharmeasy became the first unicorn in the Indian e-pharmacy segment)
-
On the USD 120 million sale of its biopharma division to Recipharm
-
On the promoters’ divestment, involving a USD 1 billion transaction
-
On its investment in Hella.Infra Market, Groww Inc, Moglix, Spinny and Progcap
-
On its investments into Quikr Mauritius Holding Private Limited, and into Capillary Technologies International Pte. Ltd.
-
On (i) The Indian aspects of its USD 1.45 billion acquisition of Capco (ii) Its USD 80 million acquisition of Eximius Design (iii) Its USD 13 million acquisition of Encore Theme Technologies (iv) Its USD 117 million acquisition of Alight HR Services India Private Limited backed by a USD 1.6 billion, 10-year outsourcing contract
-
On its USD 350 million fund raise from Prosus Ventures, TPG and existing investors (Pharmeasy became the first unicorn in the Indian e-pharmacy segment)
-
On the USD 120 million sale of its biopharma division to Recipharm
-
On the promoters’ divestment, involving a USD 1 billion transaction
-
On its investment in Hella.Infra Market, Groww Inc, Moglix, Spinny and Progcap
-
On its investments into Quikr Mauritius Holding Private Limited, and into Capillary Technologies International Pte. Ltd.
-
On (i) The Indian aspects of its USD 1.45 billion acquisition of Capco (ii) Its USD 80 million acquisition of Eximius Design (iii) Its USD 13 million acquisition of Encore Theme Technologies (iv) Its USD 117 million acquisition of Alight HR Services India Private Limited backed by a USD 1.6 billion, 10-year outsourcing contract
-
On its USD 350 million fund raise from Prosus Ventures, TPG and existing investors (Pharmeasy became the first unicorn in the Indian e-pharmacy segment)
-
On the USD 120 million sale of its biopharma division to Recipharm
-
On the promoters’ divestment, involving a USD 1 billion transaction
-
On its investment in Hella.Infra Market, Groww Inc, Moglix, Spinny and Progcap
-
On its investments into Quikr Mauritius Holding Private Limited, and into Capillary Technologies International Pte. Ltd.
-
On (i) The Indian aspects of its USD 1.45 billion acquisition of Capco (ii) Its USD 80 million acquisition of Eximius Design (iii) Its USD 13 million acquisition of Encore Theme Technologies (iv) Its USD 117 million acquisition of Alight HR Services India Private Limited backed by a USD 1.6 billion, 10-year outsourcing contract
-
On its USD 350 million fund raise from Prosus Ventures, TPG and existing investors (Pharmeasy became the first unicorn in the Indian e-pharmacy segment)
-
On the USD 120 million sale of its biopharma division to Recipharm
-
On the promoters’ divestment, involving a USD 1 billion transaction
-
On its investment in Hella.Infra Market, Groww Inc, Moglix, Spinny and Progcap
-
On its investments into Quikr Mauritius Holding Private Limited, and into Capillary Technologies International Pte. Ltd.
-
On (i) The Indian aspects of its USD 1.45 billion acquisition of Capco (ii) Its USD 80 million acquisition of Eximius Design (iii) Its USD 13 million acquisition of Encore Theme Technologies (iv) Its USD 117 million acquisition of Alight HR Services India Private Limited backed by a USD 1.6 billion, 10-year outsourcing contract
-
On its USD 350 million fund raise from Prosus Ventures, TPG and existing investors (Pharmeasy became the first unicorn in the Indian e-pharmacy segment)
-
On the USD 120 million sale of its biopharma division to Recipharm
-
On the promoters’ divestment, involving a USD 1 billion transaction
-
On its investment in Hella.Infra Market, Groww Inc, Moglix, Spinny and Progcap
-
On its investments into Quikr Mauritius Holding Private Limited, and into Capillary Technologies International Pte. Ltd.
-
On (i) The Indian aspects of its USD 1.45 billion acquisition of Capco (ii) Its USD 80 million acquisition of Eximius Design (iii) Its USD 13 million acquisition of Encore Theme Technologies (iv) Its USD 117 million acquisition of Alight HR Services India Private Limited backed by a USD 1.6 billion, 10-year outsourcing contract
-
On its USD 350 million fund raise from Prosus Ventures, TPG and existing investors (Pharmeasy became the first unicorn in the Indian e-pharmacy segment)
-
On the USD 120 million sale of its biopharma division to Recipharm
-
On the promoters’ divestment, involving a USD 1 billion transaction
-
On its investment in Hella.Infra Market, Groww Inc, Moglix, Spinny and Progcap
-
On its investments into Quikr Mauritius Holding Private Limited, and into Capillary Technologies International Pte. Ltd.
-
On (i) The Indian aspects of its USD 1.45 billion acquisition of Capco (ii) Its USD 80 million acquisition of Eximius Design (iii) Its USD 13 million acquisition of Encore Theme Technologies (iv) Its USD 117 million acquisition of Alight HR Services India Private Limited backed by a USD 1.6 billion, 10-year outsourcing contract
RECENT RECOGNITION
2023
2022
2021
2020
IFLR1000
‘Notable Practitioner’ for M&A
Legal 500 Asia Pacific
Recommended for TMT
IFLR1000
‘Notable Practitioner’ for M&A
IFLR1000
‘Notable Practitioner’ for Corporate and M&A
IFLR1000
‘Notable Practitioner’ for Corporate and M&A
RECENT RECOGNITION
IFLR1000
‘Notable Practitioner’ for M&A
Legal 500 Asia Pacific
Recommended for TMT
IFLR1000
‘Notable Practitioner’ for M&A
IFLR1000
‘Notable Practitioner’ for Corporate and M&A
IFLR1000
‘Notable Practitioner’ for Corporate and M&A